Schumann Christian, Triantafilou Kathy, Kamenz Joachim, Hanke Hartmut, Triantafilou Martha, Wittemann Silke, Joos Thomas, Hombach Vinzenz, Schneider E Marion, Lepper Philipp M
Department of Internal Medicine II, University of Ulm, Germany.
Scand J Infect Dis. 2006;38(2):139-42. doi: 10.1080/00365540500277755.
We present a case of severe sepsis due to Streptococcus pneumoniae, serotype 22F treated with recombinant human activated protein C (drotrecogin alpha activated) (DrotAA). APACHE II score at admission was 34 with a predicted mortality of 81%. A wide range of cytokines, chemokines and receptors was measured before and after DrotAA treatment. Soon after infusion of 24 microg DrotAA per kg bodyweight and h (microg/kg/h) over a period of 96 h, cytokine levels fell markedly. The patient survived and was discharged after 6 weeks of hospitalization. In conclusion, administration of DrotAA in a case of Streptococcus pneumoniae-induced septic shock was followed by dramatic changes in serum levels of immuno-regulatory cytokines.